

# CONTENTS

|  |  |
|--|--|
|  | <p><b>The Platinum Hall of Fame</b> <span style="float: right;">e117</span><br/> <a href="http://dx.doi.org/10.1016/j.eururo.2019.09.009">http://dx.doi.org/10.1016/j.eururo.2019.09.009</a></p>   |
| <p>Platinum Opinions</p>   | <p><b>MicroRNAs: Turning the Tide in Testicular Cancer</b> <span style="float: right;">541</span></p>  |
|   | <p><i>N. Singla, J.T. Lofin, A. Bagrodia</i><br/>                     MicroRNAs are poised to radically change the way we care for patients with germ cell tumors (GCTs) across all disease states, from diagnosis to managing chemorefractory disease. miR-371a-3p is a promising candidate biomarker that may precisely individualize GCT treatment paradigms.</p>   |
| <p>Platinum Priorities<br/>                     Reviews, Original Articles and Brief Correspondence together with the Full Length Editorials</p> | <p><b>Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care</b> <span style="float: right;">543</span></p>  |
|   | <p><i>W.K.B. Ranasinghe, C.A. Reichard, B.F. Chapin</i><br/>                     Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.</p>   |
| <p>Prostate Cancer</p>   | <p><b>The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management</b> <span style="float: right;">546</span></p>   |
|   | <p><i>V.R. Ramnarine, M. Kobelev, E.A. Gibb, M. Nouri, D. Lin, Y. Wang, R. Buttyan, E. Davicioni, A. Zoubeidi, C.C. Collins</i><br/>                     This review comprehensively summarises three decades of knowledge on long noncoding RNA biology and research in prostate cancer. It systematically summarises the significant contribution of these master regulators in tumorigenesis and how this translates clinically.</p>  |
|  | <p><b>Translating Science to Medicine: When Will the Rubber Meet the Road?</b> <span style="float: right;">560</span></p>  |
|   | <p><i>J.J. Tosoian, A.M. Chinnaiyan</i></p>  |
|  | <p><b>Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer</b> <span style="float: right;">562</span> </p>  |
|   | <p><i>W.S. Chen, R. Aggarwal, L. Zhang, S.G. Zhao, G.V. Thomas, T.M. Beer, D.A. Quigley, A. Foye, D. Playdle, J. Huang, P. Lloyd, E. Lu, D. Sun, X. Guan, M. Rettig, M. Gleave, C.P. Evans, J. Youngren, L. True, P. Lara, V. Kothari, Z. Xia, K.N. Chi, R.E. Reiter, C.A. Maher, F.Y. Feng, E.J. Small, J.J. Alumkal</i><br/>                     The presence of two DNA alterations in RB1 is associated with poor overall survival independently of other clinicopathologic factors in metastatic castration-resistant prostate cancer. In addition, Wnt/<math>\beta</math>-catenin pathway activation and <math>\beta</math>-catenin mutations are associated with enzalutamide resistance and poor overall survival.</p> |
|  | <p><b>Separating the Dreadful from the Merely Bad: Towards Prognostic and Predictive Biomarkers in Metastatic Castration-resistant Prostate Cancer</b> <span style="float: right;">572</span></p>  |
|   | <p><i>M. Fraser</i></p>  |

|  |     |
|--|-----|
| <p><b>High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility</b></p> <p><i>M. van der Leest, B. Israël, E.B. Cornel, P. Zámečník, I.G. Schoots, H. van der Lelij, A.R. Padhani, M. Rovers, I. van Oort, M. Sedelaar, C. Hulsbergen-van de Kaa, G. Hannink, J. Veltman, J. Barentsz</i></p> <p>Short magnetic resonance imaging (MRI) protocols improves prostate MRI accessibility at a lower direct-cost: twice as fast bi-parametric MRI is as accurate as multi-parametric MRI, only at the cost of 2% more biopsies and 1% more over-detection of low-grade prostate cancer.</p> | 574 |
| <p><b>Let's Keep It at One Step at a Time: Why Biparametric Magnetic Resonance Imaging Is Not the Priority Today</b></p> <p><i>J. Walz</i></p>   | 582 |
| <p><b>Reply to Jochen Walz. Let's Keep It at One Step at a Time: Why Biparametric Magnetic Resonance Imaging Is Not the Priority Today. Eur Urol 2019;76:582-3</b></p> <p><i>J.O. Barentsz, M.M.G. van der Leest, B. Israël</i></p>  | 584 |

|  |     |
|--|-----|
| <p><b>Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension</b></p> <p><i>G. Hackman, K. Taari, T.L. Tammela, M. Matikainen, M. Kouri, T. Joensuu, T. Luukkaala, A. Salonen, T. Isotalo, A. Pétas, N. Hendolin, P.J. Boström, S. Aaltomaa, K. Lehtoranta, P. Hellström, J. Riikonen, M. Korpela, H. Minn, P.-L. Kellokumpu-Lehtinen, E. Pukkala, A. Hemminki</i></p> <p>In a randomised setting of patients with positive margins or extracapsular extension, adjuvant radiotherapy following radical prostatectomy significantly improved biochemical recurrence-free survival compared with radical prostatectomy alone. More adverse events occurred in the radiotherapy group, although radiotherapy was generally well tolerated.</p> | 586 |
| <p><b>The Finnish Randomized Trial of Adjuvant Radiotherapy Versus Observation After Prostatectomy: Almost a Trial of Adjuvant Versus Late Salvage Radiotherapy</b></p> <p><i>D.E. Spratt</i></p>  | 596 |

Urothelial Cancer



|  |  |
|--|--|
| <p><b>Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer</b></p> <p><i>L. Wang, Y. Gong, A. Saci, P.M. Szabo, A. Martini, A. Necchi, A. Siefker-Radtke, S. Pal, E.R. Plimack, J.P. Sfakianos, N. Bhardwaj, A. Horowitz, A.M. Farkas, D. Mulholland, B.S. Fischer, W.K. Oh, P. Sharma, J. Zhu, M.D. Galsky</i></p> <p>Despite FGFR3 alterations in urothelial cancers being associated with decreased inferred T-cell infiltration, in two large clinical trial cohorts, patients with FGFR3-mutant metastatic urothelial cancers responded to immune checkpoint blockade similarly to patients with FGFR3 wild-type tumors. This disconnect may be related to decreased stromal-mediated resistance to immune checkpoint blockade in FGFR3-altered urothelial cancer, suggesting a potential "balancing out" of positive and negative predictors of immune checkpoint blockade sensitivity.</p> | <p> 599</p> |
| <p><b>Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer</b></p> <p><i>N.O. Elander, S.A. Hussain</i></p>   | 604  |

Testis Cancer



|   |     |
|---|-----|
| <p><b>Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer</b></p> <p><i>A.C. Calaway, L.H. Einhorn, T.A. Masterson, R.S. Foster, C. Cary</i></p> <p>The clinical scenarios we report should serve as a word of caution with regard to the widespread implementation of robotic operative approaches for men with germ cell tumors. It is not clear why these unusual recurrence patterns occurred, but further scrutiny going forward would be prudent.</p> | 607 |
| <p><b>Recurrence After Robotic Retroperitoneal Lymph Node Dissection Raises More Questions than Answers</b></p> <p><i>J. Porter, S. Eggener, E. Castle, P. Pierorazio</i></p>   | 610 |

|                   |   |             |
|-------------------|---|-------------|
|                   | <b>Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum</b>   | 612         |
|                   | <i>J. Sheinfeld, D.R. Feldman, R.G. DiNatale, G.J. Bosl</i>   |             |
|                   | <b>International Trends in the Incidence of Testicular Cancer: Lessons from 35 Years and 41 Countries</b>   | 615         |
|                   | <i>J.K. Gurney, A.A. Florio, A. Znaor, J. Ferlay, M. Laversanne, D. Sarfati, F. Bray, K.A. McGlynn</i>  |             |
|                   | Rates of testicular cancer are stabilising in high-incidence countries, but rapidly increasing in low-incidence countries. Understanding why this gap is closing, and why differences in rates exist between and within countries, could further our understanding of what causes this cancer.  |             |
|                   | <b>Perspectives on a Global Change in Testicular Cancer Incidence</b>   | 624         |
|                   | <i>M. Fode, C.F. Jensen, N. Azawi, P.B. Østergren</i>   |             |
| Andrology         | <b>The Prevalence of Y-chromosome Microdeletions in Oligozoospermic Men: A Systematic Review and Meta-analysis of European and North American Studies</b>   | EU*ACME 626 |
|                   | <i>T.P. Kohn, J.R. Kohn, R.C. Owen, R.M. Coward</i>   |             |
|                   | Complete Y-chromosome microdeletions (YCMs) are rarely found in men with sperm concentrations of 1–5 million sperm/ml. North American and European guidelines should be reconsidered, and clinicians do not need routine YCM screening if sperm concentrations are >1 million sperm/ml.   |             |
|                   | <b>A Refined View on the Association Between Y-chromosome Microdeletions and Sperm Concentration</b>  | 637         |
|                   | <i>C.F.S. Jensen, M. Fode, P.B. Østergren, J. Sønksen</i>   |             |
| Review            | <b>European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update</b>  | 639         |
|                   | <i>M. Babjuk, M. Burger, E.M. Compérat, P. Gontero, A.H. Mostafid, J. Palou, B.W.G. van Rhijn, M. Rouprêt, S.F. Shariat, R. Sylvester, R. Zigeuner, O. Capoun, D. Cohen, J.L.D. Escrig, V. Hernández, B. Peyronnet, T. Seisen, V. Soukup</i>  |             |
| Urothelial Cancer | The European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) present updated information on the diagnosis and treatment of this disease. Recent findings are provided for their routine application in clinical practice.  |             |
| Stone Disease     | <b>Medical Expulsive Therapy for Urinary Stones: Future Trends and Knowledge Gaps</b>   | 658         |
|                   | <i>V. De Coninck, J. Antonelli, B. Chew, J.M. Patterson, A. Skolarikos, M. Bultitude</i>  |             |
|                   | The strength of evidence for the benefit of medical expulsive therapy in ureteral stones is low, even for distal ureteral stones 5 mm.  |             |
| Surgery in Motion | <b>Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry</b>  | 667         |
|                   | <i>V. Misrai, E. Rijo, K.C. Zorn, N. Barry-Delongchamps, A. Descazeaud</i>  |             |
|                   | This prospective multicentre registry adds to the growing literature supporting the safety and reproducibility of aquablation for the treatment of benign prostatic obstruction. Despite a limited number of cases performed per surgeon, 1-yr functional outcomes appeared to be consistent with previous series.  |             |
| Original Articles | <b>Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer</b>   | 676         |
|                   | <i>A. Sharp, J.C. Welti, M.B.K. Lambros, D. Dolling, D.N. Rodrigues, L. Pope, C. Aversa, I. Figueiredo, J. Fraser, Z. Ahmad, C. Lu, P. Rescigno, M. Kolinsky, C. Bertan, G. Seed, R. Riisnaes, S. Miranda, M. Crespo, R. Pereira, A. Ferreira, G. Fowler, B. Ebbs, P. Flohr, A. Neeb, D. Bianchini, A. Petremolo, S. Sumanasuriya, A. Paschalis, J. Mateo, N. Tunariu, W. Yuan, S. Carreira, S.R. Plymate, J. Luo, J.S. de Bono</i> |             |
| Prostate Cancer   | Liquid biopsies that identify androgen receptor splice variant-7 positivity, which account for circulating tumour cell counts, could inform treatment decisions in metastatic castration-resistant prostate cancer patients.  |             |

**Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy** 686

A.S. Akthar, C. Liao, S.E. Eggener, S.L. Liauw

Patient-reported long-term quality of life (QOL) and physician-assigned late toxicity remain favorable following postprostatectomy intensity-modulated radiation therapy. Certain clinical and dosimetric risk factors may help guide decision making in consideration of preserving QOL and limiting late toxicity.

**Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts** 693

F.-J.H. Drost, D. Nieboer, T.M. Morgan, P.R. Carroll, M.J. Roobol, B. Trock

Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings.

Words of Wisdom

**Re: Scientists Rise up Against Statistical Significance** 703

J. Izard, Y. Peng, D.R. Siemens

**Re: Association of Treatment with 5 $\alpha$ -Reductase inhibitors with Time to Diagnosis and Mortality in Prostate Cancer** 704

P.C. Walsh

**Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging** 704

S.G. Koschel, L.-M. Wong, S. Heinze, H. Zargar

**Re: Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients with Castration-resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial** 705

H. van der Poel

**Re: Tea's Value as a Cancer Therapy is Steeped in Uncertainty** 706

G. Lavorgna, F. Montorsi, A. Salonia

**Re: Continuous Low-dose Antibiotic Prophylaxis for Adults with Repeated Urinary Tract Infections (AnTIC): A Randomized, Open-label Trial** 708

T.M. Kessler

Letters to the Editor published online

**Re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. <https://doi.org/10.1016/j.eururo.2019.02.028>** e125

B. Wang, H. Deng, L. Cao

**Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. <https://doi.org/10.1016/j.eururo.2019.02.028>.** e126

H. Ahmadzadehfar, M. Essler

**Re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al., Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol 2019;76:329-37** e128

X. Lin, B.T. Helfand, J. Xu

**Reply to Xiaoling Lin, Brian T. Helfand, and Jianfeng Xu's Letter to the Editor re: Daniel A. Leongamornlert, Edward J. Saunders, Sarah Wakerell, et al. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur Urol. 2019;76:329-37** e130

Z. Kote-Jarai, D.A. Leongamornlert, E.J. Saunders, D.V. Conti, R.A. Eeles

|  |                    |
|--|--------------------|
| <p><b>Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review And Meta-analysis. Eur Urol. 2019;76:284–303</b></p> <p><i>F. Montorsi, G. Gandaglia, A. Briganti</i></p>  | <p><b>e132</b></p> |
| <p><b>Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review, Meta-analysis. Eur Urol. 2019;76:284–303</b></p> <p><i>V. Kasivisvanathan, Y. Takwoingi, M. Emberton, C.M. Moore</i></p>                           | <p><b>e133</b></p> |
| <p><b>Re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4</b></p> <p><i>M. Lu, Y. Zhang, Y. Xiao</i></p>  | <p><b>e135</b></p> |
| <p><b>Reply to Mengxin Lu, Yi Zhang, Yu Xiao's Letter to the Editor, re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4</b></p> <p><i>K. Kettunen, P.J. Boström, P. Taimen</i></p>   | <p><b>e137</b></p> |
| <p><b>Re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol 2019;76:607–609</b></p> <p><i>G.J. Nason, M.A.S. Jewett, R.J. Hamilton</i></p>  | <p><b>e139</b></p> |
| <p><b>Reply to Gregory J. Nason, Michael A.S. Jewett, and Robert J. Hamilton's Letter to the Editor re: Adam C. Calaway, Lawrence H. Einhorn, Timothy A. Masterson, Richard S. Foster, Clint Cary. Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer. Eur Urol. 2019;76:607–609</b></p> <p><i>A.C. Calaway, L.H. Einhorn, T.A. Masterson, R.S. Foster, C. Cary</i></p> | <p><b>e141</b></p> |
| <p><b>Re: Giuseppe Simone, Umberto Anceschi, Gabriele Tuderti, et al. Robot-assisted Partial Adrenalectomy for the Treatment of Conn's Syndrome: Surgical Technique, and Perioperative and Functional Outcomes. Eur Urol 2019;75:811–6</b></p> <p><i>F. Gaboardi, G. Mantica, N. Suardi</i></p>  | <p><b>e142</b></p> |
| <p><b>Reply to Franco Gaboardi, Guglielmo Mantica, and Nazareno Suardi's Letter to the Editor re: Giuseppe Simone, Umberto Anceschi, Gabriele Tuderti, et al. Robot-assisted Partial Adrenalectomy for the Treatment of Conn's Syndrome: Surgical Technique, and Perioperative and Functional Outcomes. Eur Urol 2019;75:811–6</b></p> <p><i>U. Anceschi, G. Simone</i></p>  | <p><b>e144</b></p> |
| <p><b>Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. 2019;76:265–7</b></p> <p><i>A. De Bruycker, V. Fonteyne, P. Ost</i></p>  | <p><b>e147</b></p> |
| <p><b>Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol. 2019;76:265–7</b></p> <p><i>P.R. Dirix, A. Dal Pra, T. Wiegel</i></p>  | <p><b>e148</b></p> |
| <p><b>Congress Calendar</b></p>  | <p><b>e150</b></p> |

The illustration on the cover of this issue is taken from the article by Vincent Misrai, Enrique Rijo, Kevin C. Zorn, Nicolas Barry-Delongchamps, Aurelien Descazeaud, Waterjet Ablation Therapy for Treating Benign Prostatic Obstruction in Patients with Small- to Medium-size Glands: 12-month Results of the First French Aquablation Clinical Registry, which is published on pp. 667–675 of this issue.

